Overview

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Investigation of the clinical efficacy and safety of dual antiplatelet therapy with clopidogrel and cilostazol versus clopidogrel alone in preventing ischemic vascular events in patients with type 2 diabetes and symptomatic peripheral arterial disease.
Phase:
Phase 4
Details
Lead Sponsor:
University of Ioannina
Collaborator:
LIBYTEC Pharmaceutical S.A.
Treatments:
Cilostazol
Clopidogrel